We are live on ! Find out more
CNCR

ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR

Delisted

CNCR was delisted on the 27th of May, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of CNCR yet.

CNCR Hedge Fund Activity: Q3 2025 in Review

0 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2025, worth a combined $0 — down 100% from $2.24K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CNCR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Osaic Holdings, exiting entirely with an estimated $2.24K sold.

  • 0 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2025, down from 1 in Q2 2025.
  • Funds reported $0 of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2025 and 1 closed out, a net change of -1 holder.
  • The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2025 was Osaic Holdings, an estimated $2.24K sold.

Based on aggregated 13F filings for Q3 2025.